NRBO RSI Chart
Last 7 days
15.3%
Last 30 days
35.3%
Last 90 days
-12.7%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 01, 2024 | woodworth marshall h | acquired | - | - | 33,496 | chief financial officer |
Dec 01, 2023 | tursi james patrick | acquired | - | - | 32,157 | - |
Aug 11, 2023 | kim hyung heon | acquired | - | - | 625,064 | ceo & president |
Jul 27, 2023 | strickland d gordon | acquired | - | - | 100,000 | - |
Jul 27, 2023 | salsbury michael | acquired | - | - | 100,000 | - |
Jul 27, 2023 | kim na yeon | acquired | - | - | 100,000 | - |
Jul 27, 2023 | groves jason l | acquired | - | - | 100,000 | - |
Jul 27, 2023 | glickman mark a | acquired | - | - | 37,500 | - |
Jul 27, 2023 | koven andrew i | acquired | - | - | 100,000 | - |
Jul 26, 2022 | e&investment, inc. | sold | - | - | -1,445,270 | - |
Which funds bought or sold NRBO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | new | - | 63,939 | 63,939 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | 10.00 | 102 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | unchanged | - | - | 4.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -23.44 | -1,221 | 6,761 | -% |
May 15, 2024 | Hudson Bay Capital Management LP | sold off | -100 | -153,748 | - | -% |
May 14, 2024 | NORTHERN TRUST CORP | new | - | 55,248 | 55,248 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | added | 19.45 | 20,725 | 84,702 | -% |
May 10, 2024 | VANGUARD GROUP INC | new | - | 114,602 | 114,602 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | unchanged | - | 10.00 | 102 | -% |
May 10, 2024 | BlackRock Inc. | unchanged | - | 2,075 | 21,571 | -% |
Unveiling NeuroBo Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to NeuroBo Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.52 | 7.43 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.1B | 2.0B | -57.61 | 9.55 | ||||
BMRN | 14.6B | 2.5B | 71.11 | 5.91 | ||||
INCY | 12.8B | 3.8B | 17.13 | 3.39 | ||||
MID-CAP | ||||||||
BBIO | 5.8B | 107.9M | -10.63 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.22 | 9.73 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 3.1B | 240.7M | -6.6 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
NVAX | 2.0B | 996.6M | -5.07 | 2.03 | ||||
CPRX | 1.9B | 411.3M | 29.69 | 4.7 | ||||
CRBP | 489.5M | 881.7K | -14.5 | 481.06 | ||||
INO | 330.9M | 4.9M | -2.65 | 67.99 | ||||
IBIO | 15.7M | 2.1M | -0.68 | 7.61 |
NeuroBo Pharmaceuticals Inc News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -25.3% | 17.00 | 23.00 | 26.00 | 29.00 | 31.00 | 34.00 | 8.00 | 10.00 | 13.00 | 17.00 | 8.00 | 11.00 | 14.00 | 11.00 | 13.00 | 16.00 | 12.00 | 14.00 | 2.00 | 4.00 | 6.00 |
Current Assets | -25.5% | 17.00 | 23.00 | 26.00 | 29.00 | 31.00 | 34.00 | 8.00 | 10.00 | 13.00 | 17.00 | 8.00 | 10.00 | 14.00 | 11.00 | 13.00 | 15.00 | 11.00 | 14.00 | 2.00 | 4.00 | 6.00 |
Cash Equivalents | -28.7% | 16.00 | 22.00 | 26.00 | 29.00 | 31.00 | 33.00 | 6.00 | 9.00 | 12.00 | 16.00 | 7.00 | 10.00 | 13.00 | 10.00 | 12.00 | 14.00 | 10.00 | 14.00 | 21.00 | 25.00 | 2.00 |
Net PPE | 2.2% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
Liabilities | 13.9% | 7.00 | 6.00 | 5.00 | 4.00 | 11.00 | 12.00 | 2.00 | 1.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 4.00 | 4.00 | 3.00 | 4.00 | 2.00 | 3.00 | 2.00 | 2.00 |
Current Liabilities | 14.5% | 7.00 | 6.00 | 5.00 | 4.00 | 11.00 | 12.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 4.00 | 4.00 | 3.00 | 4.00 | 2.00 | 3.00 | 2.00 | 2.00 |
Shareholder's Equity | -39.6% | 10.00 | 17.00 | 22.00 | 25.00 | 21.00 | 22.00 | 6.00 | 9.00 | 12.00 | 15.00 | 6.00 | 9.00 | 13.00 | 7.00 | 10.00 | 12.00 | 8.00 | 12.00 | - | 2.00 | 4.00 |
Retained Earnings | -6.2% | -115 | -108 | -102 | -99.10 | -98.40 | -95.79 | -91.12 | -88.01 | -84.70 | -81.83 | -77.25 | -73.80 | -69.87 | -66.54 | -47.03 | -43.98 | -41.60 | -36.87 | -94.26 | -90.83 | -87.91 |
Additional Paid-In Capital | 0.1% | 125 | 125 | 124 | 124 | 119 | 118 | 97.00 | 97.00 | 97.00 | 96.00 | 83.00 | 83.00 | 83.00 | 74.00 | 57.00 | 56.00 | 49.00 | 49.00 | 93.00 | 93.00 | 92.00 |
Shares Outstanding | 0% | 5.00 | 5.00 | 5.00 | 5.00 | 3.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 7.00 | - | - | - | 7.00 | - | - | - | 31.00 | - | - | - | 23.00 | - | - | - | 10.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -88.6% | -6,400 | -3,393 | -2,814 | -2,045 | -2,547 | -1,807 | -2,359 | -2,717 | -4,829 | -2,899 | -2,507 | -3,587 | -6,141 | -2,348 | -1,954 | -2,324 | -4,138 | -1,278 | -3,345 | -1,192 | -1,224 |
Share Based Compensation | 5.0% | 105 | 100 | 172 | 24.00 | -74.00 | 218 | 218 | 211 | 207 | 188 | 107 | 180 | 187 | 160 | 209 | 171 | 159 | -75.00 | 54.00 | 79.00 | 60.00 |
Cashflow From Investing | 44.4% | -5.00 | -9.00 | -37.00 | - | -4.00 | - | - | - | - | -583 | - | - | - | 71.00 | - | - | -2.00 | -5,939 | -93.00 | - | - |
Cashflow From Financing | - | - | - | - | - | - | 28,815 | - | - | - | 12,886 | -24.00 | 72.00 | 9,092 | - | - | 6,805 | 53.00 | 1.00 | -9.00 | 34,434 | -10,259 |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 4,904 | $ 637 |
General and administrative | 1,977 | 1,883 |
Total operating expenses | 6,881 | 2,520 |
Loss from operations | (6,881) | (2,520) |
Other income (expense): | ||
Change in fair value of warrant liabilities | (70) | (84) |
Interest income | 237 | |
Total other income | 167 | (84) |
Loss before income taxes | (6,714) | (2,604) |
Provision for income taxes | 0 | 0 |
Net loss | (6,714) | (2,604) |
Comprehensive loss | $ (6,714) | $ (2,604) |
Loss per share: | ||
Net loss per share, basic | $ (1.32) | $ (0.51) |
Net loss per share, diluted | $ (1.32) | $ (0.51) |
Weighted average shares of common stock outstanding: | ||
Basic (in shares) | 5,089,408 | 5,059,003 |
Diluted (in shares) | 5,089,408 | 5,059,003 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash | $ 15,988 | $ 22,435 |
Prepaid expenses and other current assets | 776 | 77 |
Total current assets | 16,764 | 22,512 |
Property and equipment, net | 47 | 46 |
Right-of-use asset | 186 | 202 |
Other assets | 21 | 21 |
Total assets | 17,018 | 22,781 |
Current liabilities: | ||
Accounts payable (including related party payable of $794 and $0 as of March 31, 2024 and December 31, 2023, respectively) | 2,079 | 821 |
Accrued liabilities (including related party payable of $175 and $789 as of March 31, 2024 and December 31, 2023, respectively) | 3,948 | 4,414 |
Warrant liabilities | 728 | 658 |
Lease liability, short-term | 70 | 67 |
Total current liabilities | 6,825 | 5,960 |
Lease liability, long-term | 117 | 136 |
Total liabilities | 6,942 | 6,096 |
Commitments and contingencies (Note 4) | ||
Stockholders' equity | ||
Preferred stock, $0.001 par value per share; 10,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023 | ||
Common stock, $0.001 par value per share, 100,000 shares authorized as of March 31, 2024 and December 31, 2023; 4,906 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 5 | 5 |
Additional paid-in capital | 125,050 | 124,945 |
Accumulated deficit | (114,979) | (108,265) |
Total stockholders' equity | 10,076 | 16,685 |
Total liabilities and stockholders' equity | $ 17,018 | $ 22,781 |